1. Home
  2. CRSP vs RELY Comparison

CRSP vs RELY Comparison

Compare CRSP & RELY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • RELY
  • Stock Information
  • Founded
  • CRSP 2013
  • RELY 2011
  • Country
  • CRSP Switzerland
  • RELY United States
  • Employees
  • CRSP N/A
  • RELY N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • RELY Computer Software: Prepackaged Software
  • Sector
  • CRSP Health Care
  • RELY Technology
  • Exchange
  • CRSP Nasdaq
  • RELY Nasdaq
  • Market Cap
  • CRSP 4.9B
  • RELY 3.5B
  • IPO Year
  • CRSP 2016
  • RELY 2021
  • Fundamental
  • Price
  • CRSP $57.68
  • RELY $16.99
  • Analyst Decision
  • CRSP Buy
  • RELY Buy
  • Analyst Count
  • CRSP 16
  • RELY 10
  • Target Price
  • CRSP $70.73
  • RELY $27.40
  • AVG Volume (30 Days)
  • CRSP 3.7M
  • RELY 3.5M
  • Earning Date
  • CRSP 08-04-2025
  • RELY 08-06-2025
  • Dividend Yield
  • CRSP N/A
  • RELY N/A
  • EPS Growth
  • CRSP N/A
  • RELY N/A
  • EPS
  • CRSP N/A
  • RELY N/A
  • Revenue
  • CRSP $37,675,000.00
  • RELY $1,356,469,000.00
  • Revenue This Year
  • CRSP $28.31
  • RELY $27.85
  • Revenue Next Year
  • CRSP $268.05
  • RELY $20.30
  • P/E Ratio
  • CRSP N/A
  • RELY N/A
  • Revenue Growth
  • CRSP N/A
  • RELY 34.37
  • 52 Week Low
  • CRSP $30.04
  • RELY $12.43
  • 52 Week High
  • CRSP $71.13
  • RELY $27.32
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 52.32
  • RELY 34.35
  • Support Level
  • CRSP $61.13
  • RELY $16.86
  • Resistance Level
  • CRSP $69.58
  • RELY $17.40
  • Average True Range (ATR)
  • CRSP 3.89
  • RELY 0.49
  • MACD
  • CRSP -0.71
  • RELY 0.06
  • Stochastic Oscillator
  • CRSP 28.46
  • RELY 22.08

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About RELY Remitly Global Inc.

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

Share on Social Networks: